Browser storage is unavailable. Keep this page open and export your collection before leaving.
FinalDose is building the first programmable drug - a single smart drug molecule that you can insert any diseased genetic code and it can search and destroy cells upon DNA recognition. Unlocking 80% of undruggable targets today. Starting with all cancers.
CEO @ FinalDose (YC P26). Oxford PhD in Oncology. Previous startup (Vivid Dx) solved a multi-decade bottleneck in sepsis diagnostics: low biomass isolation. By overcoming this hurdle, we built the world’s fastest diagnostic system - slashing wait times from 5 days to just 30 minutes. Raised $15M in venture backing.
Founder at FinalDose (YC P26). DPhil in Biochemistry from Oxford, where he spent 5 years as a postdoctoral researcher at the MRC Weatherall Institute of Molecular Medicine. Led CRISPR screening projects uncovering new druggable targets in cancer cells and built pipelines reducing hit validation time from months to 7 days. Research focuses on BRCA1-deficient cancers and PARP inhibitor resistance mechanisms.
Cofounder and CTO at FinalDose (YC P26). Oxford PhD in Computational Biology with Wellcome Trust full scholarship. Previously Data Lead at Gutsee Biotech. Developed novel machine learning method to use coevolution biology to identify genetic targets that convey drug resistance in viruses. During SARS-CoV-2 pandemic, led UK biobank analysis of human genetics susceptibility for infections
Founded 2025 · Source
Source-based assessment · automated evidence rules
The retained text does not establish product availability or customer use.
Maturity is an evidence-based assessment, not a success rating. It may understate the current stage where evidence is limited. Coverage records documented areas, not a complete or independently audited company history.
abinitio bio is the AI-native operating platform for drug development and manufacturing.
Founders · Product · How it works
Same category · Biotech pharma
Our autonomous biodefense capabilities ensure validated point-of-care diagnostics for emerging biological threats are developed in days, not 12+ months.
Founders
Same category · Biotech pharma
Anthrogen is engineering post-modality biology. Today's modalities reflect historical contingencies in biological progress, not fundamental categories. We develop the AI systems that design modular biological machines and the…
Founders · Product
Same category · Biotech pharma
Anto is building a foundation model for microbial communities, making the gut microbiome computable for the first time. We predict drug toxicity and efficacy across diverse populations and fix drugs so they work for everyone — solving…
Founders · Product
Same category · Biotech pharma
Generative AI Medical Writing Solution for Biotech, Life Sciences, Pharma & Medical Devices | Artos AI. Book a demo online.
Customers · Founders · Product
Same category · Biotech pharma
Astraea is AI software for clinical trial teams. Build SDTM, ADaM and TFL outputs in your environment, with qualified experts reviewing every output.
Founders · Product · How it works
Same category · Biotech pharma
